Regarding studies with human biopsies, the evidence around CNT2 is controversial: while one study indicates that high expression of this protein correlates with a poor response to neoadjuvant concurrent chemoradiotherapy and worse patient outcomes for survival in rectal cancer [56], another study indicates that CNT2 expression is significantly repressed in colorectal cancer [57]. Here, SLC28A2 is linked to colorectal cancer.